Keros Therapeutics (KROS) Depreciation and Depletion (2019 - 2025)
Keros Therapeutics (KROS) reported Depreciation and Depletion of $400000.0 for Q4 2025, up 20.48% on a YoY basis from $332000.0 in Q4 2024, and up 1.27% quarter-over-quarter from $395000.0 in Q3 2025.
Keros Therapeutics (KROS) Depreciation and Depletion (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported Depreciation and Depletion for 7 years, with the latest figure at $400000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation and Depletion rose 20.48% year-over-year to $400000.0; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 22.78% YoY), and the FY2025 full-year result was $1.5 million, up 22.78% from the prior year.
- Depreciation and Depletion for Q4 2025 stood at $400000.0, up from $395000.0 in the prior quarter.
- The five-year high for Depreciation and Depletion was $400000.0 in Q4 2025, with the low at $80000.0 in Q1 2021.
- Historically, Depreciation and Depletion has averaged $230250.0 across 5 years, with a median of $228500.0 in 2023.
- Annual changes were most pronounced in 2022 — Depreciation and Depletion surged 238.46% — and 2023, when it tumbled 37.99%.
- Keros Therapeutics' Depreciation and Depletion stood at $104000.0 in 2021, then advanced by 22.12% to $127000.0 in 2022, then soared by 94.49% to $247000.0 in 2023, then surged by 34.41% to $332000.0 in 2024, then grew by 20.48% to $400000.0 in 2025.
- The last three Depreciation and Depletion figures came in at $400000.0 (Q4 2025), $395000.0 (Q3 2025), and $370000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Sep 30, 2023 | 210,000.00 |
| Sep 30, 2023 | 210,000.00 |